NASDAQ: AVXL

NASDAQ: AVXL

Fragile X syndrome

Advancing groundbreaking therapies to tackle the challenges of neurodegenerative and rare conditions.

What is Fragile X syndrome?

Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and developmental delays. It is a genetic condition that affects learning, behavior, and social interactions, often presenting alongside physical and emotional challenges.

On a Deeper Level

Fragile X Syndrome is a genetic disorder caused by a mutation in the FMR1 gene located on the X chromosome. This mutation prevents the production of a protein called FMRP, which is essential for normal brain development and functioning. As a result, individuals with FXS experience a range of cognitive, behavioral, and physical challenges. FXS typically manifests in early childhood, with delayed speech and motor milestones being some of the first noticeable signs. The condition affects both males and females, but males often experience more severe symptoms due to the single X chromosome. While there is no cure for Fragile X Syndrome, early intervention and tailored support can significantly improve outcomes for individuals and their families.

Signs & Symptoms

The signs and symptoms of Fragile X Syndrome vary in severity but commonly include:

  • Cognitive challenges: Learning disabilities and difficulties with problem-solving.
  • Behavioral issues: Hyperactivity, anxiety, and sensory sensitivities.
  • Social difficulties: Shyness, difficulty maintaining eye contact, and challenges with social interactions.
  • Physical features: Prominent ears, a long face, and flexible joints.
  • Speech and language delays: Delayed onset of speech and repetitive speech patterns.

These symptoms often co-occur with other conditions, such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).

How many are affected by this condition?

Prevalence

Fragile X Syndrome affects approximately 1 in 4,000 males and 1 in 8,000 females worldwide. It is the most common single-gene cause of autism spectrum disorder and intellectual disability, making it a significant concern for families, educators, and healthcare providers.

Insights and Data

  • The exact number of people who have FXS is unknown, but a review of research studies estimated that about 1 in 7,000 males and about 1 in 11,000 females have been diagnosed with FXS. (CDC, 2024).
  • Approximately 30-50% of individuals with Fragile X Syndrome also meet the criteria for autism spectrum disorder (National Fragile X Foundation, 2024).
  • Early intervention can improve developmental outcomes, particularly in language, motor skills, and social interactions.

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.

Continue
Go Back